Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Cardiology-CTVS
  • Cardiology & CTVS News
  • Bisoprolol in CAD -...

Bisoprolol in CAD - Key Insights from National Consensus 2025 with Special Focus on Women

Dr. Prem AggarwalWritten by Dr. Prem Aggarwal Published On 2025-07-10T11:39:29+05:30  |  Updated On 10 July 2025 4:36 PM IST
Bisoprolol in CAD - Key Insights from National Consensus 2025 with Special Focus on Women
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

Bisoprolol is reaffirmed as a key cardioselective Beta-1-blocker across the cardiovascular disease (CVD) continuum, with a special focus on its clinical utility in women with coronary artery disease (CAD), as reported in a recently released national consensus by Indian experts.

The consensus, published in the May 2025 issue of JAPI, was developed by Indian cardiologists, physicians, and a multispecialty panel through a rigorous review of clinical trials, real-world data, clinical guidelines, and gender-specific considerations. It highlights the need for equitable, evidence-based cardiovascular care and supports greater implementation of β1-selective therapy in women, who are often underrepresented in clinical trials. Below are the key insights from the national consensus:

Cardiovascular Disease in Indian Women

CVD poses a significant yet under-recognized burden among Indian women across all age groups. As the consensus emphasized, “Women bear a significant burden across all age groups, with factors like hormonal changes, obesity, and social barriers requiring tailored approaches.”

CAD presents differently in women compared to men, with more frequent non-obstructive disease, narrower arteries, diffuse atherosclerosis, and atypical symptoms. These factors contribute to underdiagnosis and delayed care. Postmenopausal women are especially vulnerable and experience significantly higher mortality following myocardial infarction (MI).

Despite a lower overall incidence of MI, women experience higher mortality following acute coronary events, partly due to atypical symptoms like fatigue, nausea, or anxiety rather than classic chest pain. Postmenopausal women face elevated risk for heart failure with preserved ejection fraction (HFpEF) and Takotsubo cardiomyopathy due to arterial stiffness and hormonal withdrawal.

Bisoprolol: A First-Line Choice for Women with CAD

The consensus reaffirmed bisoprolol as the preferred β1-selective β-blocker for women with CAD, including stable angina, post-MI care, ST-elevation and non-ST-elevation MI (STEMI/NSTEMI), and atrial fibrillation (AF) with rapid ventricular response. Early initiation at low doses is associated with significant reductions in all-cause mortality, major adverse cardiac events (MACEs), and ventricular arrhythmias (VA).

In women with coexisting heart failure (HF), bisoprolol improves left ventricular ejection fraction (LVEF), survival, and reduces hospitalizations. Its cardioselectivity, metabolic neutrality, and favorable tolerability make it suitable for women with diabetes, asthma, or chronic obstructive pulmonary disease (COPD).

Tailored Utility of Bisoprolol in Comorbidities

Bisoprolol’s pharmacological profile makes it especially valuable for women with multiple chronic conditions. In those with chronic kidney disease (CKD), it offers cardiovascular protection by maintaining blood pressure stability during dialysis—an advantage attributed to its minimal dialyzability.

The drug is well tolerated during pregnancy and lactation under medical supervision, with no developmental harm observed in breastfed infants.

In postmenopausal women, bisoprolol contributes to skeletal health, as it reduces fracture risk through positive effects on BMD and microarchitecture, offering additional value in this high-risk population.

In women with asthma or COPD, bisoprolol’s high β1-selectivity minimizes the risk of bronchospasm, while its metabolic neutrality makes it suitable for those with diabetes or metabolic syndrome, avoiding adverse effects on glucose and lipid profiles.

Diagnostic and Therapeutic Disparities

The consensus highlighted persistent gender-based inequities in CVD care, citing “systemic under-recognition and gender bias in treatment pathways” as key contributors. Women are less likely to receive timely diagnosis or advanced imaging and are underprescribed high-intensity therapies, including β-blockers.

Importance of Uninterrupted Bisoprolol Treatment in CAD: Latest ABYSS Trial from EuroPCR 2025

Findings from the AβYSS (Assessment of β-blocker interruption one Year after an uncomplicated myocardial infarction on Safety and Symptomatic cardiac events) trial, published in May 2025 in the European Heart Journal, highlight that interruption of β-blocker therapy—predominantly bisoprolol (used in 71.5% of 3,698 patients and ~20% of the cohort were women)—after MI led to sustained increases in systolic blood pressure (+3.7 mmHg) and heart rate (+9.8 beats per minute), with a higher incidence of adverse cardiovascular outcomes, especially in patients with hypertension.

Despite greater benefits from cardiac resynchronization therapy (CRT) in women, referral rates remain low, while higher surgical risks and reduced participation in cardiac rehabilitation continue to compromise outcomes.

Closing the Gender Gap in CAD Care

Despite proven benefits, bisoprolol remains underutilized in women, often due to clinical hesitancy in those with borderline BP or bradycardia. The panel urged a shift toward gender-equitable prescribing and highlighted the need for better female representation in CVD trials. “Gender-equitable diagnosis, guideline-directed treatment, and proactive use of cardioselective agents like bisoprolol can bridge outcome disparities in Indian women,” the report concluded.

References:

1. Chopra HK, Sethi KK, Nair T. et al. National Consensus Statement on Role of Bisoprolol across Cardiovascular Continuum: Special Focus on Women. J Assoc Physicians India 2025;73(5):e16–e33.

2. Procopi N, Zeitouni M, Kerneis M, et al. Beta-blocker interruption effects on blood pressure and heart rate after myocardial infarction: the AβYSS trial. European Heart Journal. 2025;ehaf170. doi:10.1093/eurheartj/ehaf170. Published online May 14, 2025.

bisoprololcadcoronary artery diseasebisoprolol in cadbeta blockerbeta blocker in cadcad in women coronary artery disease womencad risk in womenconcorbisoprolol consensusbisoprolol safetybisoprolol efficacybisoprolol 2025 consensusjapiabyss trialeuropcreuropean heart journalcardiac resynchronization therapyvamicvdmyocardial infarctionlvefatrial fibrillation
Dr. Prem Aggarwal
Dr. Prem Aggarwal

Dr Prem Aggarwal, (MD Medicine, DNB Cardiology) is a Cardiologist by profession and also the Co-founder and Chairman of Medical Dialogues. He focuses on news and perspectives about cardiology, and medicine related developments at Medical Dialogues. He can be reached out at drprem@medicaldialogues.in

Show Full Article
Next Story

Editorial

Bisoprolol in CAD - Key Insights from National Consensus 2025 with Special Focus on Women

Bisoprolol in CAD - Key Insights from National Consensus 2025 with Special Focus on Women

Featured image representing orthopaedic care

Modern Orthopaedic Care: How Is Technology Improving Movement and Recovery? - Dr Abhijit Lonari

Aspirin in Primary Prevention of Stroke-Review of Evidence Through the Needs of Indian Clinical Settings

Aspirin in Primary Prevention of Stroke-Review of Evidence Through the Needs of Indian Clinical...

Dapagliflozin Shines in Post-TAVI Patients:DAPA-TAVI Trial Findings

Dapagliflozin Shines in Post-TAVI Patients:DAPA-TAVI Trial Findings

Identifying Candidates for Aspirin in Primary Prevention: Men Aged 40-50 with Hypertension, Dyslipidemia, and Familial ASCVD Risk

Identifying Candidates for Aspirin in Primary Prevention: Men Aged 40-50 with Hypertension,...

View All

Journal Club Today

Managing Acne Prone Skin - Dermatologist Dr Sai Sandeepthi

Managing Acne Prone Skin - Dermatologist Dr Sai Sandeepthi

View All

Health News Today

Health Bulletin 10/July/ 2025

Health Bulletin 10/July/ 2025

View All
© 2022 All Rights Reserved.
Powered By: Hocalwire
X
We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok